FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378672729> ?p ?o ?g. }

• W4378672729 endingPage "358" @default.
• W4378672729 startingPage "357" @default.
• W4378672729 abstract "We read the interesting review published by Tacquard et al.1 and appreciated the effort to provide evidence on the epidemiology, clinical manifestations, and management of perioperative anaphylaxis. While we recommend reading this review to the practitioner who wishes to better understand the mechanisms underlying drug-induced hypersensitivity reactions and anaphylaxis, we would comment on the statement, “pretreatment with antihistamines and glucocorticoids can reduce the severity or frequency of certain non-immunologic reactions, including those to radiocontrast media.”Premedication with corticosteroids and antihistamines is still widely used to prevent immediate and delayed hypersensitivity reactions. Although its use is diffusely believed to reduce the severity of anaphylaxis and incidence of biphasic reactions, the evidence supporting these practices is limited, and the potential adverse effect of corticosteroids is underestimated.2The European Academy of Allergy and Clinical Immunology Anaphylaxis (Zurich, Switzerland) recently updated the guidelines for the diagnosis and prevention of anaphylaxis. The European Academy of Allergy and Clinical Immunology Anaphylaxis task force makes no recommendation for or against premedication to prevent anaphylaxis due to insufficient evidence about its effectiveness. It should be noted, however, that the quality of evidence for this recommendation is very low.3The International Suspected Perioperative Allergic Reaction consensus states that prophylaxis with antihistamines or corticosteroids in patients with a past medical history of hypersensitivity reactions does not appear to prevent or reduce the severity of anaphylaxis. Antihistamines, however, seem to play a potential role in preventing mild reactions caused by nonspecific histamine release.4The prevalence of radiocontrast-associated hypersensitivity reactions has decreased in recent years due to the advent of low-osmolality nonionic radiocontrast agents. Clinical manifestations are usually mild or moderate and are caused by immune-mediated or non–immune-mediated mast cell activation. A recent systematic review on anaphylaxis focuses on the use of antihistamines and corticosteroids for the prevention of hypersensitivity reactions. The authors conclude that premedication reduces hypersensitivity reactions associated with chemotherapy and allergen immunotherapy. On the other hand, premedication in patients with previous radiocontrast adverse reactions is not recommended due to the lack of significant benefit; corticosteroids and antihistamines fail to prevent both acute- and delayed-onset reactions.5For the same reasons, the European guidelines on radiocontrast media do not recommend any premedication.6 Conversely, the U.S. guidelines recommend it in high-risk patients, although the authors state that premedication “does not prevent all contrast reactions” and likely induces a diagnostic delay.7The Italian Medicines Agency (Rome, Italy) recently released updated recommendations for the prevention and management of radiocontrast-associated hypersensitivity reactions. The document focuses on the importance of an accurate patient’s medical history and, in case of a positive history of previous hypersensitivity reaction, the usefulness of an allergologic assessment. Pretreatment with antihistamines and glucocorticoids does not prevent a recurrence and might cause the clinician to underestimate potential red flags.8Thanks to the thoughtful insights derived from the paper by Tacquard et al.,1 we had the opportunity to examine the recent evidence available to date on perioperative anaphylaxis. We agree that in specific situations such as immunologic disorders (i.e., recurrent angioedema or mastocytosis), premedication with corticosteroids and antihistamines is strongly recommended. However, the efficacy of antihistamines and corticosteroids in preventing and reducing the severity of anaphylaxis is not yet well-defined.9 Future high-quality evidence is needed to draw a definitive statement on pharmacologic prophylaxis for perioperative anaphylaxis.Dr. Brazzi declares no competing interests. He reports receiving travel and speaker funding, unrelated to this work, from Getinge (Göteborg, Sveden), being a consultant for Siare Engineering International Group (Bologna, Italy), and providing expert medical testimony for B.Braun (Melsungen, Germany). The other authors declare no competing interests." @default.
• W4378672729 created "2023-05-30" @default.
• W4378672729 creator A5002143975 @default.
• W4378672729 creator A5007878836 @default.
• W4378672729 creator A5046307132 @default.
• W4378672729 creator A5069948590 @default.
• W4378672729 creator A5089529161 @default.
• W4378672729 date "2023-05-29" @default.
• W4378672729 modified "2023-09-26" @default.
• W4378672729 title "Perioperative Anaphylaxis: Comment" @default.
• W4378672729 cites W1975094261 @default.
• W4378672729 cites W2753827468 @default.
• W4378672729 cites W2944915877 @default.
• W4378672729 cites W3001375137 @default.
• W4378672729 cites W3192902361 @default.
• W4378672729 cites W4309648740 @default.
• W4378672729 doi "https://doi.org/10.1097/aln.0000000000004594" @default.
• W4378672729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37247351" @default.
• W4378672729 hasPublicationYear "2023" @default.
• W4378672729 type Work @default.
• W4378672729 citedByCount "1" @default.
• W4378672729 countsByYear W43786727292023 @default.
• W4378672729 crossrefType "journal-article" @default.
• W4378672729 hasAuthorship W4378672729A5002143975 @default.
• W4378672729 hasAuthorship W4378672729A5007878836 @default.
• W4378672729 hasAuthorship W4378672729A5046307132 @default.
• W4378672729 hasAuthorship W4378672729A5069948590 @default.
• W4378672729 hasAuthorship W4378672729A5089529161 @default.
• W4378672729 hasConcept C16005928 @default.
• W4378672729 hasConcept C177713679 @default.
• W4378672729 hasConcept C203014093 @default.
• W4378672729 hasConcept C207480886 @default.
• W4378672729 hasConcept C2775933838 @default.
• W4378672729 hasConcept C2778300832 @default.
• W4378672729 hasConcept C2779060952 @default.
• W4378672729 hasConcept C2993280485 @default.
• W4378672729 hasConcept C31174226 @default.
• W4378672729 hasConcept C42219234 @default.
• W4378672729 hasConcept C71924100 @default.
• W4378672729 hasConceptScore W4378672729C16005928 @default.
• W4378672729 hasConceptScore W4378672729C177713679 @default.
• W4378672729 hasConceptScore W4378672729C203014093 @default.
• W4378672729 hasConceptScore W4378672729C207480886 @default.
• W4378672729 hasConceptScore W4378672729C2775933838 @default.
• W4378672729 hasConceptScore W4378672729C2778300832 @default.
• W4378672729 hasConceptScore W4378672729C2779060952 @default.
• W4378672729 hasConceptScore W4378672729C2993280485 @default.
• W4378672729 hasConceptScore W4378672729C31174226 @default.
• W4378672729 hasConceptScore W4378672729C42219234 @default.
• W4378672729 hasConceptScore W4378672729C71924100 @default.
• W4378672729 hasIssue "3" @default.
• W4378672729 hasLocation W43786727291 @default.
• W4378672729 hasLocation W43786727292 @default.
• W4378672729 hasOpenAccess W4378672729 @default.
• W4378672729 hasPrimaryLocation W43786727291 @default.
• W4378672729 hasRelatedWork W1906382642 @default.
• W4378672729 hasRelatedWork W2074945661 @default.
• W4378672729 hasRelatedWork W2092665604 @default.
• W4378672729 hasRelatedWork W2164600535 @default.
• W4378672729 hasRelatedWork W2397980766 @default.
• W4378672729 hasRelatedWork W2973408097 @default.
• W4378672729 hasRelatedWork W3012514343 @default.
• W4378672729 hasRelatedWork W3032303464 @default.
• W4378672729 hasRelatedWork W3035986814 @default.
• W4378672729 hasRelatedWork W4280546142 @default.
• W4378672729 hasVolume "139" @default.
• W4378672729 isParatext "false" @default.
• W4378672729 isRetracted "false" @default.
• W4378672729 workType "article" @default.